Plejd levererade ett rekordstarkt första kvartal med en nettoomsättning om 307,9 MSEK (220,4), motsv...
* We raise our '26 oil price estimate to USD 81/bbl (prev.
Upsales meddelar att styrelsen föreslår en utdelning och separat notering av det nyutvecklade AI-bol...
In this update, we are refining the portfolio’s balance between high-conviction growth and rigorous ...
CellaVision digitaliserar blodanalys och frigör viktig tid för sjukvården.
Redeye shares its preview of Bonesupport Q1 2026 results, due April 22.
* We see 3% organic growth in Q1, supported by cold January weather * Swedish and Norwegian earnings...
* Q1e: 2.8m EEs, -15% sales growth, 18% (37%) EBIT margin * FX headwinds to abate from Q2, market ou...
Alligator Bioscience has announced a letter-of-intent (LOI) with Unicancer regarding mitazalimab, ou...
This afternoon, OssDsign released preliminary Q1 figures.
Redeye briefly comments on ExpreS2ion’s announcement of a published Hong Kong patent application cov...
Last Wednesday, Redeye hosted an investor forum. Redeye Investor Forum was a live broadcast in which...
Duell’s sales were flat organically and ahead of our and FactSet consensus expectations in Q2, while...
* Xplora has the tools to drive a good senior conversion rate * We forecast a ~30% EBITA CAGR from '...
Redeye is positive on Senzime’s secured contracts with one of the world’s largest IDNs.
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q1 2026 ended a...
Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunother...
Redeye shares its preview of Xvivo’s Q1 2026 results, due on April 24.